MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy.
Puneeth Shridhar, Michael S Glennon, Soumojit Pal, Christina J Waldron, Ethan J Chetkof, Payel Basak, Nicolas G Clavere, Dipanjan Banerjee, Sebastien Gingras, Jason R Becker
Author Information
Puneeth Shridhar: Division of Cardiology, Department of Medicine, and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (P.S., M.S.G., S.P., C.J.W., E.J.C., P.B., N.C.G., D.B., J.R.B.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA.
Michael S Glennon: Division of Cardiology, Department of Medicine, and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (P.S., M.S.G., S.P., C.J.W., E.J.C., P.B., N.C.G., D.B., J.R.B.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA.
Soumojit Pal: Division of Cardiology, Department of Medicine, and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (P.S., M.S.G., S.P., C.J.W., E.J.C., P.B., N.C.G., D.B., J.R.B.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA. ORCID
Christina J Waldron: Division of Cardiology, Department of Medicine, and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (P.S., M.S.G., S.P., C.J.W., E.J.C., P.B., N.C.G., D.B., J.R.B.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA.
Ethan J Chetkof: Division of Cardiology, Department of Medicine, and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (P.S., M.S.G., S.P., C.J.W., E.J.C., P.B., N.C.G., D.B., J.R.B.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA.
Payel Basak: Division of Cardiology, Department of Medicine, and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (P.S., M.S.G., S.P., C.J.W., E.J.C., P.B., N.C.G., D.B., J.R.B.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA.
Nicolas G Clavere: Division of Cardiology, Department of Medicine, and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (P.S., M.S.G., S.P., C.J.W., E.J.C., P.B., N.C.G., D.B., J.R.B.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA.
Dipanjan Banerjee: Division of Cardiology, Department of Medicine, and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (P.S., M.S.G., S.P., C.J.W., E.J.C., P.B., N.C.G., D.B., J.R.B.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA. ORCID
Sebastien Gingras: Department of Immunology (S.G.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA. ORCID
Jason R Becker: Division of Cardiology, Department of Medicine, and Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute (P.S., M.S.G., S.P., C.J.W., E.J.C., P.B., N.C.G., D.B., J.R.B.), University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA. ORCID
BACKGROUND: Microvasculature dysfunction is a common finding in pathologic remodeling of the heart and is thought to play an important role in the pathogenesis of hypertrophic cardiomyopathy (HCM), a disease caused by sarcomere gene mutations. We hypothesized that microvascular dysfunction in HCM was secondary to abnormal microvascular growth and could occur independent of ventricular hypertrophy. METHODS: We used multimodality imaging methods to track the temporality of microvascular dysfunction in HCM mouse models harboring mutations in the sarcomere genes (cardiac myosin binding protein C3) or (myosin heavy chain 6). We performed complementary molecular methods to assess protein quantity, interactions, and post-translational modifications to identify mechanisms regulating this response. We manipulated select molecular pathways in vivo using both genetic and pharmacological methods to validate these mechanisms. RESULTS: We found that microvascular dysfunction in our HCM models occurred secondary to reduced myocardial capillary growth during the early postnatal time period and could occur before the onset of myocardial hypertrophy. We discovered that the E3 ubiquitin protein ligase MDM2 (murine double minute 2) dynamically regulates the protein stability of both HIF1α (hypoxia-inducible factor 1 alpha) and HIF2α (hypoxia-inducible factor 2 alpha)/EPAS1 (endothelial PAS domain protein 1) through canonical and noncanonical mechanisms. The resulting HIF imbalance leads to reduced proangiogenic gene expression during a key period of myocardial capillary growth. Reducing MDM2 protein levels by genetic or pharmacological methods normalized HIF protein levels and prevented the development of microvascular dysfunction in both HCM models. CONCLUSIONS: Our results show that sarcomere mutations induce cardiomyocyte MDM2 signaling during the earliest stages of disease, and this leads to long-term changes in the myocardial microenvironment.
